lysergic acid diethylamide has been researched along with Neoplasms in 23 studies
Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.
lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases." | 9.19 | Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. ( Brenneisen, R; Doblin, R; Gasser, P; Holstein, D; Michel, Y; Passie, T; Yazar-Klosinski, B, 2014) |
| "We aim to provide an evidence-based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin." | 5.41 | Are psychedelics the answer to chronic pain: A review of current literature. ( Kooijman, NI; Kramers, C; Mulleners, WM; Reuser, A; van der Wal, SEI; Vissers, KCP; Willegers, T, 2023) |
| "A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases." | 5.19 | Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. ( Brenneisen, R; Doblin, R; Gasser, P; Holstein, D; Michel, Y; Passie, T; Yazar-Klosinski, B, 2014) |
| "psilocybin, LSD) in treating cancer-related psychiatric distress." | 2.58 | Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. ( Ross, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (60.87) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Barnett, BS | 1 |
| Ziegler, K | 1 |
| Doblin, R | 2 |
| Carlo, AD | 1 |
| Kooijman, NI | 1 |
| Willegers, T | 1 |
| Reuser, A | 1 |
| Mulleners, WM | 1 |
| Kramers, C | 1 |
| Vissers, KCP | 1 |
| van der Wal, SEI | 1 |
| Simonsson, O | 1 |
| Sexton, JD | 1 |
| Hendricks, PS | 1 |
| Ross, S | 1 |
| Gasser, P | 2 |
| Holstein, D | 1 |
| Michel, Y | 1 |
| Yazar-Klosinski, B | 1 |
| Passie, T | 2 |
| Brenneisen, R | 1 |
| Kirchner, K | 1 |
| Spiegel, D | 1 |
| Stix, G | 1 |
| SJOERDSMA, A | 1 |
| KORNETSKY, C | 1 |
| EVARTS, EV | 1 |
| SCOTT, KG | 2 |
| DANIELS, AE | 1 |
| DAY, M | 1 |
| STOCKBRIDGE, A | 1 |
| STONE, RS | 1 |
| Li, JH | 1 |
| Lin, LF | 1 |
| Phifer, B | 1 |
| Grof, S | 1 |
| Goodman, LE | 2 |
| Richards, WA | 2 |
| Kurland, AA | 2 |
| Kast, E | 2 |
| Jackson, LG | 1 |
| Bishun, NP | 1 |
| Raven, RW | 1 |
| Williams, DC | 1 |
| Monti, M | 1 |
| Louria, DB | 1 |
| Smith, JK | 1 |
| Finkel, GC | 1 |
| Pahnke, WN | 1 |
| Jarvik, LF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life[NCT05403086] | Phase 2 | 100 participants (Anticipated) | Interventional | 2024-01-14 | Not yet recruiting | ||
| LSD-assisted Psychotherapy in Persons Suffering From Anxiety Associated With Advanced-stage Life Threatening Diseases. A Phase-II, Double-blind, Placebo-controlled Dose-response Pilot Study[NCT00920387] | Phase 2 | 12 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| EMPOWER Study: Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids: Observational Study With First Responders and Military Personnel Examining Previous Use Experience and Interest in Participating in Future Research S[NCT04965740] | 102 participants (Actual) | Observational | 2021-06-04 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The STAI-state subscale is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Participants respond to each item by selecting a response from a 4-point Likert scale ranging from 4 (Not at all) to 1 (Very much so). STAI-state scores are summed for a total score that range from 20 to 80, with higher scores indicating greater state anxiety. The STAI-trait subscale also consists of 20-items and is scored the same way, with total scores ranging from 20 to 80, with higher scores indicating greater trait anxiety." (NCT00920387)
Timeframe: Baseline (Visit 4)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| STAI-state | STAI-trait | |
| Active Placebo LSD (20 mcg) | 47.7 | 43.3 |
| Full Dose LSD (200 mcg) | 53.1 | 53.2 |
"The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The STAI-state subscale is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Participants respond to each item by selecting a response from a 4-point Likert scale ranging from 4 (Not at all) to 1 (Very much so). STAI-state scores are summed for a total score that range from 20 to 80, with higher scores indicating greater state anxiety. The STAI-trait subscale also consists of 20-items and is scored the same way, with total scores ranging from 20 to 80, with higher scores indicating greater trait anxiety." (NCT00920387)
Timeframe: 2 months after second experimental session
| Intervention | score on a scale (Mean) | |
|---|---|---|
| STAI-state | STAI-trait | |
| Active Placebo LSD (20 mcg) | 51.7 | 49.0 |
| Full Dose LSD (200 mcg) | 41.5 | 45.2 |
5 reviews available for lysergic acid diethylamide and Neoplasms
| Article | Year |
|---|---|
Are psychedelics the answer to chronic pain: A review of current literature.
Topics: Chronic Pain; Cluster Headache; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psiloc | 2023 |
Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
Topics: Anxiety; Depression; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psilocybin; Serot | 2018 |
Genetic toxicology of abused drugs: a brief review.
Topics: Animals; Areca; Cannabis; Carcinogens; Chromosome Aberrations; Cocaine; Humans; Illicit Drugs; Lyser | 1998 |
Chromosomes and cancer.
Topics: Carcinogens; Cell Transformation, Neoplastic; Cells, Cultured; Chromosome Aberrations; Chromosome Di | 1974 |
[Teratogenic effects of LSD].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Aged; Animals; Child; Chromosome Aberrations; Female | 1968 |
3 trials available for lysergic acid diethylamide and Neoplasms
| Article | Year |
|---|---|
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up | 2014 |
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up | 2014 |
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up | 2014 |
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up | 2014 |
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects.
Topics: Adult; Anxiety Disorders; Double-Blind Method; Emotions; Female; Follow-Up Studies; Humans; Lysergic | 2015 |
LSD-assisted psychotherapy in patients with terminal cancer.
Topics: Adult; Aged; Anxiety; Attitude to Death; Clinical Trials as Topic; Depression; Female; Humans; Lyser | 1973 |
15 other studies available for lysergic acid diethylamide and Neoplasms
| Article | Year |
|---|---|
Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data.
Topics: Adult; Hallucinogens; Hematologic Neoplasms; Humans; Lysergic Acid Diethylamide; Neoplasms; Phenethy | 2022 |
Associations between lifetime classic psychedelic use and markers of physical health.
Topics: Adult; Body Mass Index; Drug Users; Female; Hallucinogens; Health Status; Heart Diseases; Humans; Ly | 2021 |
Psilocybin-assisted psychotherapy for dying cancer patients - aiding the final trip.
Topics: Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psilocybin; Psychotherapy | 2016 |
Return of a problem child.
Topics: Anxiety; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psilocybin | 2009 |
Lysergic acid diethylamide in patients with excess serotonin.
Topics: Carcinoid Tumor; Digestive System Neoplasms; Ergot Alkaloids; Gastrointestinal Tract; Lysergic Acid | 1956 |
THE SIMILAR ACTION OF LYSERGIC ACID DERIVATIVES, HYPERTENSIN (CIBA) AND ALDOSTERONE UPON RB86 UPTAKE BY RED BLOOD CELLS FROM CONTROL AND CANCER SUBJECTS.
Topics: Adenocarcinoma; Aldosterone; Angiotensin Amide; Angiotensins; Carcinoma, Squamous Cell; Erythrocytes | 1963 |
THE EFFECTS OF DRUGS ON THE UPTAKE OF AMINES BY MAST CELLS.
Topics: Amines; Animals; Chlorpromazine; Cocaine; Ethanolamines; Guanethidine; Hallucinogens; Histamine; Imi | 1964 |
The anti-tumor action of lysergic acid derivatives and their serotonin-blocking effect as reflected by the I 131 distribution in rats.
Topics: Animals; Antineoplastic Agents; Iodine; Lysergic Acid; Lysergic Acid Diethylamide; Neoplasms; Radioi | 1959 |
A review of the research and theological implications of the use of psychedelic drugs with terminal cancer patients.
Topics: Human Experimentation; Humans; Informed Consent; Lysergic Acid Diethylamide; Neoplasms; Psychotropic | 1977 |
LSD and the dying patient.
Topics: Chlorpromazine; Death; Humans; Lysergic Acid Diethylamide; Neoplasms; Palliative Care | 1966 |
Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide.
Topics: Affect; Analgesics; Attitude; Fear; Hallucinations; Humans; Lysergic Acid Diethylamide; Middle Aged; | 1967 |
Chromosome aberrations--red herring or red flag?
Topics: Alkylating Agents; Anemia, Aplastic; Ataxia Telangiectasia; Benzene; Chromosome Aberrations; Down Sy | 1973 |
Mycotoxins other than aflatoxins: tumor-producing potential and possible relation to human disease.
Topics: Anemia, Aplastic; Animals; Edible Grain; Ergotism; Foodborne Diseases; Hallucinations; Humans; Leuke | 1970 |
LSD-assisted psychotherapy with terminal cancer patients.
Topics: Adult; Female; Humans; Lysergic Acid Diethylamide; Male; Middle Aged; Neoplasms; Psychotherapy; Term | 1969 |
Contradictions in LSD research.
Topics: Abnormalities, Drug-Induced; Chromosomes; Lysergic Acid Diethylamide; Neoplasms | 1968 |